Austin Health

Title
Diagnostic delay in pulmonary arterial hypertension: Insights from the Australian and New Zealand pulmonary hypertension registry.
Publication Date
2020-08
Author(s)
Khou, Victor
Anderson, James J
Strange, Geoff
Corrigan, Carolyn
Collins, Nicholas
Celermajer, David S
Dwyer, Nathan
Feenstra, John
Horrigan, Mark
Keating, Dominic
Kotlyar, Eugene
Lavender, Melanie
McWilliams, Tanya J
Steele, Peter
Weintraub, Robert
Whitford, Helen
Whyte, Ken
Williams, Trevor J
Wrobel, Jeremy P
Keogh, Anne
Lau, Edmund M
Subject
cohort studies
delayed diagnosis
mortality
pulmonary hypertension
survival analysis
Type of document
Journal Article
OrcId
0000-0002-1890-6092
0000-0002-6593-1717
0000-0001-6150-6927
0000-0003-1473-0437
DOI
10.1111/resp.13768
Abstract
Early diagnosis of PAH is clinically challenging. Patterns of diagnostic delay in Australian and New Zealand PAH populations have not been explored in large-scale studies. We aimed to evaluate the magnitude, risk factors and survival impact of diagnostic delay in Australian and New Zealand PAH patients. A cohort study of PAH patients from the PHSANZ Registry diagnosed from 2004 to 2017 was performed. Diagnostic interval was the time from symptom onset to diagnostic right heart catheterization as recorded in the registry. Factors associated with diagnostic delay were analysed in a multivariate logistic regression model. Survival rates were compared across patients based on the time to diagnosis using Kaplan-Meier method and Cox regression. A total of 2044 patients were included in analysis. At diagnosis, median age was 58 years (IQR: 43-69), female-to-male ratio was 2.8:1 and majority of patients were in NYHA FC III-IV (82%). Median diagnostic interval was 1.2 years (IQR: 0.6-2.7). Age, CHD-PAH, obstructive sleep apnoea and peripheral vascular disease were independently associated with diagnostic interval of ≥1 year. No improvement in diagnostic interval was seen during the study period. Longer diagnostic interval was associated with decreased 5-year survival. PAH patients experience significant diagnostic interval, which has not improved despite increased community awareness. Age, cardiovascular and respiratory comorbidities are significantly associated with longer time to diagnosis. Mortality rates appear higher in patients who experience longer diagnostic interval.
Link
Citation
Respirology 2020; 25(8): 863-871
Jornal Title
Respirology

Files:

NameSizeformatDescriptionLink